You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIloperidone
Accession NumberDB04946
TypeSmall Molecule
GroupsApproved
DescriptionIloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. made initial inquiries into the drug; however, in May 1996, they discontinued research, and in June 1997 gave research rights to Titan Pharmaceuticals. Titan then handed over worldwide development, manufacturing and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals announced that the Phase III development rights have been acquired by Vanda Pharmaceuticals. FDA approved on May 9, 2009.
Structure
Thumb
Synonyms
1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone
4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone
Fanapt
Fanapta
HP 873
Iloperidona
Iloperidonum
Zomaril
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FanaptKitOralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
FanaptTablet12 mg/1OralVanda Pharmaceuticals Inc.2016-10-15Not applicableUs
FanaptTablet1 mg/1OralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
FanaptTablet10 mg/1OralVanda Pharmaceuticals Inc.2016-01-15Not applicableUs
FanaptTablet8 mg/1OralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
FanaptTablet4 mg/1OralVanda Pharmaceuticals Inc.2015-12-15Not applicableUs
FanaptTablet2 mg/1OralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
FanaptTablet1 mg/1OralVanda Pharmaceuticals Inc.2016-05-01Not applicableUs
FanaptTablet10 mg/1OralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
FanaptTablet8 mg/1OralVanda Pharmaceuticals Inc.2015-09-15Not applicableUs
FanaptTablet4 mg/1OralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
FanaptTablet2 mg/1OralVanda Pharmaceuticals Inc.2016-08-01Not applicableUs
FanaptTablet12 mg/1OralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
FanaptKitOralVanda Pharmaceuticals Inc.2015-12-01Not applicableUs
FanaptTablet6 mg/1OralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
FanaptTablet6 mg/1OralVanda Pharmaceuticals Inc.2016-07-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FiaptaNot Available
ZomarilNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIVPO7KJ050N
CAS number133454-47-4
WeightAverage: 426.4806
Monoisotopic: 426.195485567
Chemical FormulaC24H27FN2O4
InChI KeyXMXHEBAFVSFQEX-UHFFFAOYSA-N
InChI
InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3
IUPAC Name
1-(4-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy}-3-methoxyphenyl)ethan-1-one
SMILES
COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O
Pharmacology
IndicationTreatment of acute schizophrenia.
Structured Indications
PharmacodynamicsIloperidone shows high affinity and maximal receptor occupancy for dopamine D2 receptors in the caudate nucleus and putamen of the brains of schizophrenic patients. The improvement in cognition is attributed to iloperidone's high affinity for α adrenergic receptors. Iloperidone also binds with high affinity to serotonin 5-HT2a and dopamine 3 receptors. Iloperidone binds with moderate affinity to dopamine D4, serotonin 5-HT6 and 5-HT7, and norepinephrine NEα1 receptors. Furthermore, iloperidone binds with weak affinity to serotonin 5-HT1A, dopamine D1, and histamine H1 receptors.
Mechanism of actionIloperidone is a dopamine D2 and 5-HT2A receptor antagonist and acts as a neuroleptic agent.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
D(3) dopamine receptorProteinunknown
antagonist
HumanP35462 details
D(4) dopamine receptorProteinunknown
antagonist
HumanP21917 details
5-hydroxytryptamine receptor 1AProteinunknown
antagonist
HumanP08908 details
5-hydroxytryptamine receptor 6Proteinunknown
antagonist
HumanP50406 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Alpha-2C adrenergic receptorProteinunknown
antagonist
HumanP18825 details
Related Articles
AbsorptionWell absorbed from the GI tract and Cmax is reached within 2-4 hours. Steady-state concentration is achieved in 3-4 days post-administration of iloperidone. Relative bioavailability of the tablet formulation compared to oral solution is 96%. Accumulation occurs in a predictable fashion.
Volume of distribution

Apparent Vd = 1340-2800 L

Protein binding95% of iloperidone is bound to protein. Percent bound is not altered by renal or hepatic impairment or combination therapy with ketoconazole.
Metabolism

Iloperidone is hepatically metabolized by cytochrome enzymes which mediates O-dealkylation (CYP3A4), hydroxylation (CYP2D6), and decarboxylation/reduction processes. Metabolites formed are P89, P95, and P88. The minor metabolite is P89, whereas P95 and P88 are the major ones. The affinity of the iloperidone metabolite P88 is generally equal or less than that of the parent compound. In contrast, the metabolite P95 only shows affinity for 5-HT2A (Ki value of 3.91) and the NEα1A, NEα1B, NEα1D, and NEα2C receptors (Ki values of 4.7, 2.7, 8.8 and 4.7 nM respectively).

Route of eliminationRenal (in which <1% of iloperidone is excreted unchanged).
Half lifeThe observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.
Clearance

Apparent clearance (clearance/bioavilability) = 47-102 L/h.

ToxicityCommonly observed adverse reactions (incidence ≥5% and two-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Iloperidone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineIloperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineIloperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineIloperidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineIloperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Iloperidone.Experimental
AbirateroneThe serum concentration of Iloperidone can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Iloperidone.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Iloperidone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Iloperidone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Iloperidone.Withdrawn
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Iloperidone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Iloperidone.Approved, Investigational
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Iloperidone.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Iloperidone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Iloperidone.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Iloperidone.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Iloperidone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Iloperidone.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Iloperidone.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Iloperidone.Approved
AmiodaroneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Iloperidone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Iloperidone.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Iloperidone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Iloperidone.Experimental
AmphetamineIloperidone may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideAnagrelide may increase the QTc-prolonging activities of Iloperidone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
AprepitantThe serum concentration of Iloperidone can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Iloperidone.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
ArtemetherIloperidone may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Iloperidone.Approved
AsenapineIloperidone may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Iloperidone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Iloperidone.Vet Approved
AzelastineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Iloperidone.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Iloperidone.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Iloperidone.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Iloperidone.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Iloperidone.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Iloperidone.Approved
BenperidolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Iloperidone.Approved
BenzphetamineIloperidone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Iloperidone.Approved
BetaxololThe metabolism of Iloperidone can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Iloperidone can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Boceprevir.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
BosentanThe serum concentration of Iloperidone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Iloperidone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Iloperidone.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Iloperidone.Approved, Illicit
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Iloperidone.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Iloperidone.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Iloperidone.Approved, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Iloperidone.Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Iloperidone.Approved, Investigational
BuprenorphineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Iloperidone.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Iloperidone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Iloperidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Iloperidone.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Iloperidone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Iloperidone.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Iloperidone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Iloperidone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Iloperidone.Approved
CaffeineThe metabolism of Iloperidone can be decreased when combined with Caffeine.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.Approved
CarbamazepineThe metabolism of Iloperidone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Iloperidone.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Iloperidone.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Iloperidone.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Iloperidone.Experimental
CelecoxibThe metabolism of Iloperidone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Iloperidone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Iloperidone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Iloperidone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Iloperidone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Iloperidone.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iloperidone.Approved
ChlorphentermineIloperidone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Iloperidone.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Iloperidone.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Iloperidone.Approved
CholecalciferolThe metabolism of Iloperidone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Iloperidone.Experimental
CimetidineThe metabolism of Iloperidone can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Iloperidone.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Iloperidone.Approved
ClarithromycinThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Clarithromycin.Approved
ClemastineThe metabolism of Iloperidone can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Iloperidone.Approved
ClobazamThe metabolism of Iloperidone can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Iloperidone.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Iloperidone.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Iloperidone.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Iloperidone.Approved, Illicit
ClotrimazoleThe metabolism of Iloperidone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Iloperidone.Approved
CobicistatThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Cobicistat.Approved
CocaineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Iloperidone.Approved, Illicit
ConivaptanThe serum concentration of Iloperidone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Iloperidone.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Iloperidone.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Iloperidone.Approved
CyclosporineThe metabolism of Iloperidone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Iloperidone.Approved
Cyproterone acetateThe serum concentration of Iloperidone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Iloperidone can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Iloperidone.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Iloperidone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Iloperidone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Darunavir.Approved
DasatinibThe serum concentration of Iloperidone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Iloperidone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Iloperidone.Approved
DelavirdineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Iloperidone.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Iloperidone.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Iloperidone.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Iloperidone.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Iloperidone.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Iloperidone.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Iloperidone.Vet Approved
DexamethasoneThe serum concentration of Iloperidone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iloperidone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Iloperidone.Approved, Vet Approved
DextroamphetamineIloperidone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Iloperidone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Iloperidone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Iloperidone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Iloperidone.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Iloperidone.Approved, Illicit, Vet Approved
DiethylpropionIloperidone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Iloperidone.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Iloperidone.Approved, Illicit
DihydroergotamineThe metabolism of Iloperidone can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Iloperidone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Iloperidone.Experimental, Illicit
DiltiazemThe metabolism of Iloperidone can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Iloperidone.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Iloperidone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Iloperidone.Approved, Illicit
DisopyramideDisopyramide may increase the QTc-prolonging activities of Iloperidone.Approved
DisulfiramThe metabolism of Iloperidone can be decreased when combined with Disulfiram.Approved
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Iloperidone.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Iloperidone.Approved
DomperidoneDomperidone may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Iloperidone.Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Iloperidone.Approved
DoxycyclineThe metabolism of Iloperidone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Iloperidone.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Illicit
DronedaroneDronedarone may increase the QTc-prolonging activities of Iloperidone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Iloperidone.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Iloperidone.Approved
DuloxetineThe metabolism of Iloperidone can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Iloperidone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Iloperidone.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Iloperidone.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Iloperidone can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Iloperidone.Approved, Investigational
EliglustatIloperidone may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Iloperidone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Iloperidone.Approved, Investigational
EnzalutamideThe serum concentration of Iloperidone can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iloperidone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Iloperidone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Iloperidone.Approved
EribulinEribulin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Iloperidone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Iloperidone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Iloperidone.Approved
EthanolIloperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iloperidone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iloperidone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Iloperidone.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Iloperidone.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Iloperidone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Iloperidone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Iloperidone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Iloperidone.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Iloperidone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Iloperidone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Iloperidone.Illicit, Vet Approved
EtravirineThe serum concentration of Iloperidone can be decreased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Iloperidone.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Iloperidone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Iloperidone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Iloperidone.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Iloperidone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Iloperidone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Iloperidone.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Iloperidone.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Iloperidone.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Iloperidone.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Iloperidone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Iloperidone.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Iloperidone.Approved, Illicit
FluoxetineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Iloperidone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Iloperidone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Iloperidone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Iloperidone.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Iloperidone.Approved
FluvoxamineThe metabolism of Iloperidone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
FosamprenavirThe metabolism of Iloperidone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Iloperidone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Iloperidone.Approved
FosphenytoinThe metabolism of Iloperidone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Iloperidone.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Iloperidone.Approved, Investigational
Fusidic AcidThe serum concentration of Iloperidone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Iloperidone.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Iloperidone is combined with gabapentin enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Iloperidone.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Iloperidone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Iloperidone.Approved, Illicit
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Iloperidone is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Iloperidone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Iloperidone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Iloperidone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Iloperidone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Iloperidone.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Iloperidone.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Iloperidone.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Iloperidone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Iloperidone.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Iloperidone.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Iloperidone.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Iloperidone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Iloperidone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Iloperidone.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Iloperidone.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Iloperidone.Approved
HydrocodoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Iloperidone.Approved, Illicit
Hydroxyamphetamine hydrobromideIloperidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Iloperidone.Approved
IdelalisibThe serum concentration of Iloperidone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Iloperidone can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Iloperidone.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Iloperidone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Iloperidone.Approved
IndinavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Indinavir.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Iloperidone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Iloperidone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Iloperidone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Iloperidone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Iloperidone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Iloperidone.Approved
IsavuconazoniumThe metabolism of Iloperidone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Iloperidone.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
IsoniazidThe metabolism of Iloperidone can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Iloperidone.Approved
ItraconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Iloperidone.Approved
IvacaftorThe serum concentration of Iloperidone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Iloperidone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Iloperidone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Iloperidone.Approved
KetoconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Iloperidone.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Iloperidone.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Iloperidone.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Iloperidone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Iloperidone.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Iloperidone.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Iloperidone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Iloperidone.Approved
LidocaineThe metabolism of Iloperidone can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Iloperidone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Iloperidone.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Iloperidone.Approved
LisdexamfetamineIloperidone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Iloperidone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Iloperidone.Illicit
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Iloperidone.Approved
LopinavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Iloperidone.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Iloperidone.Approved
LorcaserinThe metabolism of Iloperidone can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Iloperidone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Iloperidone.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Iloperidone.Investigational
LuliconazoleThe serum concentration of Iloperidone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Iloperidone can be increased when combined with Lumacaftor.Approved
LumefantrineIloperidone may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Iloperidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Vet Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Iloperidone.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Iloperidone.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Iloperidone.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Iloperidone.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Iloperidone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Iloperidone.Approved
MephedroneIloperidone may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineIloperidone may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Iloperidone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Iloperidone.Approved, Illicit
MequitazineIloperidone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Iloperidone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Iloperidone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Iloperidone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Iloperidone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Iloperidone.Approved, Illicit
MethamphetamineIloperidone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Iloperidone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Iloperidone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Iloperidone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Iloperidone.Approved
MethotrimeprazineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Iloperidone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Iloperidone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Iloperidone.Approved, Investigational
MetoprololThe metabolism of Iloperidone can be decreased when combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Iloperidone.Approved
MetyrosineIloperidone may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Iloperidone can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Iloperidone.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Iloperidone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Iloperidone.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Iloperidone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Iloperidone.Approved
MirtazapineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Iloperidone.Approved, Investigational
MitotaneThe serum concentration of Iloperidone can be decreased when it is combined with Mitotane.Approved
MMDAIloperidone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Iloperidone.Approved
ModafinilThe serum concentration of Iloperidone can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Iloperidone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Iloperidone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Iloperidone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Investigational
NafcillinThe serum concentration of Iloperidone can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Iloperidone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Iloperidone.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Iloperidone.Approved, Investigational
NefazodoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nelfinavir.Approved
NetupitantThe serum concentration of Iloperidone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Iloperidone can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Iloperidone.Approved
NicotineThe metabolism of Iloperidone can be decreased when combined with Nicotine.Approved
NilotinibNilotinib may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Iloperidone.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Iloperidone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Iloperidone.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Iloperidone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Iloperidone.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
OlaparibThe metabolism of Iloperidone can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Iloperidone.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Iloperidone.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Iloperidone.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Iloperidone.Approved, Illicit
OrphenadrineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Iloperidone.Investigational
OsimertinibThe serum concentration of Iloperidone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Iloperidone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Iloperidone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Iloperidone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Iloperidone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iloperidone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
PalbociclibThe serum concentration of Iloperidone can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the QTc-prolonging activities of Iloperidone.Approved
PanobinostatThe serum concentration of Iloperidone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeIloperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Iloperidone.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Iloperidone.Approved
Peginterferon alfa-2bThe serum concentration of Iloperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Iloperidone.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Iloperidone.Approved, Vet Approved
PentobarbitalThe metabolism of Iloperidone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Iloperidone.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Iloperidone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Iloperidone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Iloperidone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Iloperidone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Iloperidone.Approved, Withdrawn
PhenobarbitalThe metabolism of Iloperidone can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Iloperidone.Approved
PhentermineIloperidone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe metabolism of Iloperidone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Iloperidone.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Iloperidone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Iloperidone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Iloperidone.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Iloperidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleIloperidone may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Iloperidone.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Iloperidone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Iloperidone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Iloperidone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Iloperidone.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Iloperidone.Approved
PrimidoneThe metabolism of Iloperidone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Iloperidone.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Iloperidone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Iloperidone.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iloperidone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Iloperidone.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Iloperidone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Iloperidone.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Iloperidone.Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Iloperidone.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Iloperidone.Investigational
PseudoephedrineIloperidone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Iloperidone.Approved, Illicit
QuetiapineQuetiapine may increase the QTc-prolonging activities of Iloperidone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Iloperidone.Approved
QuinidineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Quinidine.Approved
QuinineQuinine may increase the QTc-prolonging activities of Iloperidone.Approved
RacloprideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Iloperidone.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Iloperidone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Iloperidone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Iloperidone.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Iloperidone.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Iloperidone.Approved
RifabutinThe metabolism of Iloperidone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Iloperidone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Iloperidone can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Iloperidone.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ritanserin.Investigational
RitobegronIloperidone may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Iloperidone.Approved
RolapitantThe metabolism of Iloperidone can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Iloperidone.Vet Approved
RopiniroleIloperidone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Iloperidone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Iloperidone.Approved, Investigational
RotigotineIloperidone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Iloperidone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Iloperidone.Experimental
Sage 547The risk or severity of adverse effects can be increased when Iloperidone is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Iloperidone.Approved
SaquinavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Iloperidone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iloperidone.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Iloperidone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Iloperidone.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Iloperidone.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Iloperidone.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
SildenafilThe metabolism of Iloperidone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Iloperidone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Iloperidone can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Iloperidone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Iloperidone.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Iloperidone.Approved
St. John's WortThe serum concentration of Iloperidone can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Iloperidone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Iloperidone.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Iloperidone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Iloperidone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Iloperidone.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
SuvorexantIloperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenTamoxifen may increase the QTc-prolonging activities of Iloperidone.Approved
TandospironeThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Iloperidone.Approved
TelaprevirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Iloperidone.Approved
TelithromycinThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Iloperidone.Approved
TenofovirThe metabolism of Iloperidone can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Iloperidone.Approved
TeriflunomideThe serum concentration of Iloperidone can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Iloperidone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Iloperidone.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Iloperidone.Investigational
ThalidomideIloperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Iloperidone can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Iloperidone.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Iloperidone.Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Iloperidone.Approved, Vet Approved
ThioridazineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Iloperidone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Iloperidone.Approved
TiaprideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tiapride.Investigational
TiclopidineThe metabolism of Iloperidone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Iloperidone.Vet Approved
TipranavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Iloperidone.Approved
TocilizumabThe serum concentration of Iloperidone can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Iloperidone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Iloperidone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iloperidone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Iloperidone.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Iloperidone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Iloperidone.Experimental
TranylcypromineThe metabolism of Iloperidone can be decreased when combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Iloperidone.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Iloperidone.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Iloperidone.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Iloperidone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Iloperidone.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Iloperidone.Withdrawn
Uc1010The risk or severity of adverse effects can be increased when Iloperidone is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Iloperidone.Approved, Investigational
VandetanibIloperidone may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Iloperidone.Approved
VemurafenibThe serum concentration of Iloperidone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Iloperidone.Approved
VerapamilThe metabolism of Iloperidone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Iloperidone.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Iloperidone.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Iloperidone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Iloperidone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Iloperidone.Approved, Investigational
VoriconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Iloperidone.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Iloperidone.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Iloperidone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Iloperidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Iloperidone.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Iloperidone.Approved, Investigational
ZolpidemIloperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Iloperidone.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Iloperidone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Iloperidone.Approved
ZuclopenthixolZuclopenthixol may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
Food Interactions
  • Administration of iloperidone with a standard high-fat meal did not significantly affect the Cmax or AUC of iloperidone, P88, or P95, but delayed Tmax by 1 hour for iloperidone, 2 hours for P88 and 6 hours for P95.
  • Can be taken with or without meals
References
Synthesis Reference

DrugSyn.org

US5364866
General References
  1. Strupczewski JT, Bordeau KJ, Chiang Y, Glamkowski EJ, Conway PG, Corbett R, Hartman HB, Szewczak MR, Wilmot CA, Helsley GC: 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem. 1995 Mar 31;38(7):1119-31. [PubMed:7707315 ]
  2. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A: Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996 Dec 19;317(2-3):417-23. [PubMed:8997630 ]
  3. Hesselink JM: Iloperidone (Novartis). IDrugs. 2002 Jan;5(1):84-90. [PubMed:12861482 ]
  4. Hesselink JM: Iloperidone (Hoechst Marion Roussel Inc). IDrugs. 1999 Jun;2(6):584-90. [PubMed:16127622 ]
  5. Szewczak MR, Corbett R, Rush DK, Wilmot CA, Conway PG, Strupczewski JT, Cornfeldt M: The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther. 1995 Sep;274(3):1404-13. [PubMed:7562515 ]
  6. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
  7. Citrome L: Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64. doi: 10.1517/17425255.2010.531259. Epub 2010 Nov 1. [PubMed:21034370 ]
External Links
ATC CodesN05AX14
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (352 KB)
MSDSDownload (480 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9848
Caco-2 permeable+0.5513
P-glycoprotein substrateSubstrate0.6668
P-glycoprotein inhibitor IInhibitor0.8242
P-glycoprotein inhibitor IIInhibitor0.9268
Renal organic cation transporterInhibitor0.5726
CYP450 2C9 substrateNon-substrate0.9051
CYP450 2D6 substrateSubstrate0.892
CYP450 3A4 substrateSubstrate0.7409
CYP450 1A2 substrateNon-inhibitor0.6111
CYP450 2C9 inhibitorNon-inhibitor0.5061
CYP450 2D6 inhibitorNon-inhibitor0.886
CYP450 2C19 inhibitorInhibitor0.6257
CYP450 3A4 inhibitorInhibitor0.6777
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9008
Ames testNon AMES toxic0.6314
CarcinogenicityNon-carcinogens0.8699
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7862 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6563
hERG inhibition (predictor II)Inhibitor0.7945
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
KitOral
TabletOral1 mg/1
TabletOral10 mg/1
TabletOral12 mg/1
TabletOral2 mg/1
TabletOral4 mg/1
TabletOral6 mg/1
TabletOral8 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8586610 No2007-11-022027-11-02Us
US8652776 No2010-08-312030-08-31Us
US8999638 No2010-10-282030-10-28Us
US9072742 No2011-01-162031-01-16Us
US9074254 No2011-12-282031-12-28Us
US9074255 No2010-12-172030-12-17Us
US9074256 No2011-02-102031-02-10Us
US9138432 No2005-09-302025-09-30Us
US9157121 No2010-04-052030-04-05Us
USRE39198 No1996-11-152016-11-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0304 mg/mLALOGPS
logP4.26ALOGPS
logP3.22ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)16.14ChemAxon
pKa (Strongest Basic)7.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area64.8 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity116.65 m3·mol-1ChemAxon
Polarizability46.51 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzisoxazoles. These are aromatic compounds containing a benzene ring fused to an isoxazole ring. Isoxazole is five-membered ring with three carbon atoms, and an oxygen atom next to a nitrogen atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzisoxazoles
Sub ClassNot Available
Direct ParentBenzisoxazoles
Alternative Parents
Substituents
  • Benzisoxazole
  • Acetophenone
  • Methoxybenzene
  • Aryl alkyl ketone
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Anisole
  • Aralkylamine
  • Fluorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Oxazole
  • Isoxazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A: Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996 Dec 19;317(2-3):417-23. [PubMed:8997630 ]
  2. Hesselink JM: Iloperidone (Novartis). IDrugs. 2002 Jan;5(1):84-90. [PubMed:12861482 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A: Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996 Dec 19;317(2-3):417-23. [PubMed:8997630 ]
  2. Hesselink JM: Iloperidone (Novartis). IDrugs. 2002 Jan;5(1):84-90. [PubMed:12861482 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
  2. Citrome L: Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64. doi: 10.1517/17425255.2010.531259. Epub 2010 Nov 1. [PubMed:21034370 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
  2. Citrome L: Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64. doi: 10.1517/17425255.2010.531259. Epub 2010 Nov 1. [PubMed:21034370 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on December 02, 2016 02:43